New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
Big Pharma’s ‘patient advocacy’ needs to remember patients’ needs
Every year, pharmaceutical companies spend millions on “patient advocacy.” At its best, this supports families, advances science, and…
FDA’s top drug regulator, George Tidmarsh, put on leave amid probe
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA moves to ease path for biosimilars as Trump seeks to cut drug costs – statnews.com
FDA moves to ease path for biosimilars as Trump seeks to cut drug costs statnews.comHHS Sec. Robert F. Kennedy…
What To Know About President Trump’s Cognitive Test
In this week’s edition of InnovationRx, we look at President Trump’s cognitive test, Nvidia’s collaborations in life sciences…
FDA approves Blenrep, a GSK blood cancer drug with unusual history
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Eli Lilly, Sarepta, Pfizer, Medicare, Novo: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Health Care Inc.: STAT investigates hospital infections reporting
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. ~*~*~Don’t talk to…
aTyr Pharma’s Phase 3 Sarcoidosis Drug Misses Primary Endpoint
aTyr Pharma (Nasdaq: ATYR) announced topline results from its Phase…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Trump tax bill, ACA, Medicare Advantage
Tara Bannow covers hospitals, providers, and insurers. You can reach Tara on Signal at tarabannow.70. This is the…
Health care CEO salaries, UnitedHealth’s busy week
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…